


**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of: ALDERSON et al.

Application Serial No.: 09/499,468

Filed: February 7, 2000

Title: Vascular Endothelial Growth Factor-2



Group Art Unit: 1633

Examiner: Sorbello, E.

Atty. Docket No.: PF112U1

**RECEIVED**  
DEC 27 2001  
TECH CENTER 1600/2900

**SECOND SUPPLEMENTAL INFORMATION DISCLOSURE**  
**STATEMENT PURSUANT TO 37 § CFR 1.56**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of a claim of the subject application, Attorneys for Applicants hereby direct the Examiner's attention to the Statutory Declarations and accompanying exhibits as follows:

- (a) Statutory Declaration of John Stanley Mattick, and Exhibits JSM1-JSM4;
- (b) Statutory Declaration of Nicholas Kim Hayward, and Exhibits NKH1-2;
- (c) Statutory Declaration of Jennifer Ruth Gamble and Exhibits JRG1-3;
- (d) Statutory Declaration of Tom Rapoport and Exhibits TP1-2;
- (e) Statutory Declaration of Stuart A. Aaronson and Curriculum Vitae of Stuart A. Aaronson;
- (f) Statutory Declaration of Susan Power, Appendices 1-2 and Figure 1; and
- (g) Statutory Declaration of Gary Baxter Cox and Exhibits GBC-1 – GBC 23.

The above-listed declarations and accompanying exhibits were brought to the attention of the Applicants in connection with an opposition to an Australian application that

essentially corresponds to the U.S. priority application in this case. A copy of the above-listed Declarations and accompanying exhibits thereto, are enclosed.

The above information is presented so that the Patent and Trademark Office can determine any materiality thereof to the claimed invention. See 37 CFR 1.104(a) concerning the PTO duty to consider and use any such information. It is respectfully requested that the information be considered during the prosecution of this application.


Identification of the listed reference(s) is not to be construed an admission of any individual associated with the filing or prosecution of the subject application that such references are available as "prior art" against the subject application. Furthermore, Applicants do not waive any rights to appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the subject application.

Applicants respectfully request that the Examiner acknowledge receipt of the enclosed Declaration and exhibits attached thereto, in the file of the instant application.

Pursuant to 37 C.F.R. § 1.97(b), since this information disclosure statement is being filed before the mailing date of a first Office Action on the merits, no fee is due in connection herewith. However, should the Patent Office determine otherwise, please charge the required fee to Human Genome Sciences, Inc., deposit account no. 08-3425. A Fee Transmittal is also enclosed.

Respectfully submitted,

Dated: 12/21/01

  
Michele M. Wales (Reg. No. 43,975)  
Attorney for Applicants

**Human Genome Sciences, Inc.**  
9410 Key West Avenue  
Rockville, Maryland 20850  
Telephone: (301) 610-5772

Enclosures  
MMW/AKR/lcc